Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Issue 1 (8th October 2020)

• Record Type: Journal Article
• Authors: Bihorel, Sébastien; Singhal, Shalabh; Shevell, Diane; Sun, Huadong; Xie, Jenny; Basdeo, Shenita; Liu, Ang; Dutta, Santanu; Ludwig, Elizabeth; Huang, Hannah; Lin, Kuan‐ju; Fura, Aberra; Throup, John; Girgis, Ihab G.
• Is Part Of: Clinical pharmacology in drug development. Volume 10:Issue 1(2021)
• Page Start: 8
• Page End: 21
• Publication Date: 2020-10-08
• Subjects: ALC -- BMS‐986166 -- heart rate -- PK/PD -- S1P1R; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.878
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Sphingosine‐1‐phosphate (S1P) binding to the S1P‐1 receptor (S1P1R) controls the egress of lymphocytes from lymphoid organs and targets modulation of immune responses in autoimmune diseases. Pharmacologic modulation of S1P receptors has been linked to heart rate reduction. BMS‐986166, a prodrug of the active phosphorylated metabolite BMS‐986166‐P, presents an improved cardiac safety profile in preclinical studies compared to other S1P1R modulators. The pharmacokinetics, safety, and pharmacodynamics of BMS‐986166 versus placebo after single (0.75–5.0 mg) and repeated (0.25–1.5 mg/day) oral administration were assessed in healthy participants after a 1‐day lead‐in placebo period. A population model was developed to jointly describe BMS‐986166 and BMS‐986166‐P pharmacokinetics and predict individual exposures. Inhibitory sigmoid models described the relationships between average daily BMS‐986166‐P concentrations and nadir of time‐matched (day –1) placebo‐corrected heart rate on day 1 (nDDHR, where DD represents ∆∆) and nadir of absolute lymphocyte count (nALC). Predicted decreases in nDDHR and nALC were 9 bpm and 20% following placebo, with maximum decreases of 10 bpm in nDDHR due to drug effect, and approximately 80% in nALC due to drug and placebo. A 0.5‐mg/day dose regimen achieves the target 65% reduction in nALC associated with a 2‐bpm decrease in nDDHR over placebo.